BIO:ON Insight #22 · Oct 27, 2026
Buy it, extend it or build it? Three companies, three growth plans
Celltrion licenses Kaigene's KG013 for up to $580.5M, the FDA grants Ultomiris accelerated approval in IgA nephropathy, and AbbVie's lutikizumab wins phase 3 but misses expectations. Buy, extend or build: three companies, three answers.
What I learned this week
After reading all three, I found myself asking not whether something succeeded but what it was compared with. A biosimilar maker turned drug hunter, a marketed drug found a fifth job, and a phase 3 win was marked down against the market's eye. Next time you meet a "success" headline, ask "compared with what?" See you next issue. 🙏
Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.
Stories in this issue
- Pipeline Analysis
Celltrion licenses Kaigene's autoimmune antibody KG013 for up to $580.5M
CelltrionKaigeneKG013
- FDA Approvals
AstraZeneca's Ultomiris wins accelerated FDA approval in IgA nephropathy, its fifth indication
AstraZenecaAlexionUltomirisUS FDA
- Clinical Trials
AbbVie's lutikizumab hits its phase 3 HS endpoint but misses expectations; Avalo falls 35%
AbbVielutikizumabAvalo
AI summary
- 1Celltrion licensed Kaigene's preclinical autoimmune antibody KG013 (APRIL-targeting, first indication IgA nephropathy) for up to $580.5M, with the upfront undisclosed.
- 2AstraZeneca's (Alexion) Ultomiris won FDA accelerated approval in IgA nephropathy, its fifth US indication, cutting proteinuria 43.4% versus placebo at 34 weeks.
- 3AbbVie's lutikizumab met its phase 3 primary endpoint in hidradenitis suppurativa (HiSCR75 31.4% vs 23.4%) but fell short of expectations, and rival Avalo's shares fell 35%.
Relevant rolesBDRegulatory affairsClinical developmentInvestment & IR
Summary and tags generated by AI from the issue text.
References
- 1.Celltrion picks up another Kaigene autoimmune antibody for up to $580.5M (opens in a new tab)
Fierce Biotech, Oct 22, 2026
- 2.AZ's Ultomiris adds 5th rare disease feather to cap with FDA IgAN nod (opens in a new tab)
Fierce Pharma, Oct 22, 2026
- 3.AbbVie scratches out phase 3 hidradenitis suppurativa win but falls short of expectations (opens in a new tab)
Fierce Biotech, Oct 22, 2026
Related insights
Other issues covering the same companies, drugs or topics